Slide 1: ArcticZymes Technologies
A ArcticZymes Technologies
Slide 2: Agenda
Agenda 1 Highlights Q3 2020 2 ArcticZymes update 3 BetaGlucans update 4 Q3 Financials 5 Outlook
Slide 3: Highlights
Chapter 1 Highlights
Slide 4: Highlights Q3 2020
Highlights Q3 2020 Strong underlying growth Group sales YTD Largest Therapeutic Biotec BetaGlucans exceed NOK 100 order received yet continues to operate mill. NOK 3.0 mill profitably ArcticZymes 2nd best Molecular quarterly sales Diagnostic sales performance NOK efforts towards 19.5 mill. (NOK 12.0
Slide 5: ArcticZymes update
Chapter 2 ArcticZymes update
Slide 6: ArcticZymes Updates
ArcticZymes Updates Commercial - Strong underlying sales growth Therapeutics Research & Covid-19 Upsides Diagnostics ✓ Strong growth continues ✓ Molecular Diagnostics sales ✓ Lower upsides compared to Q2 ✓ 52% contribution to total sales continues to grows ✓ 20% contribution of total sales ✓ Largest
Slide 7: Geographical Expansion
Geographical Expansion Sales in China and India Efforts to enter developing and new Asian markets are materialising with new business China Supply agreement signed with Simcere Diagnostics > integrated HL-SAN into a diagnostic Next Generation Sequencing (NGS) technology This marks our first step int
Slide 8: ArcticZymes Update: Innovations
ArcticZymes Update Innovations Salt Active Nuclease Upscaling* Soon initiate the first medium-scale pilot production batch Assuming successful, this will be followed by a large-scale pilot batch Viral Diagnostics Components* Progress underway in the expression and purifying of thermostable polymeras
Slide 9: ArcticZymes Update: Operational Expansion
ArcticZymes Update Organic Growth: Operational Expansion Preparing to expand both production and R&D Today the enzymes business is operating on 2 separate sites in Tromsø Plan to bring the business together onto one site at SIVA R&D lab space will be expanded in order to capitalize on ramping up its
Slide 10: BetaGlucans update
Chapter 3 BetaGlucans update
Slide 11: Biotec BetaGlucans
Biotec BetaGlucans Operating profitably Animal Health Consumer SBG® Woulgan® Health (Adjuvant) • M-Glucan® sales continue • Continued to achieved • Expedited 3rd SBG® order • Sales deliver to expectation to fluctuate quarterly growth in M-Gard® sales relating to commitments • Following discontinuati
Slide 12: Financials
Chapter 4 Financials
Slide 13: ArcticZymes Sales Q3 2020
ArcticZymes Sales Q3 2020 Still at high levels Sales per segment Sales growth of 63% 40 000 Amounts in NOK 1.000' Therapeutics (SAN) Underlying business growth (excl. COVID-19 35 000 Research and Diagnostics upsides) of 30% 30 000 COVID-19 (upsides) Therapeutics segment (SAN) continues to 25 000 del
Slide 14: ArcticZymes Performance
ArcticZymes Performance Amounts in NOK 1.000' 40 000 Enzymes Q3 YTD (Amounts in NOK 1.000) 2020 2019 2020 2019 35 000 Sales revenues 19 546 11 986 71 395 28 857 Sales Operating expenses -10 657 -8 535 -28 649 -25 078 30 000 EBITDA 9 510 3 831 44 612 5 289 EBITDA 25 000 20 000 15 000 10 000 5 000 0 Q
Slide 15: BetaGlucans Sales Q3 2020
BetaGlucans Sales Q3 2020 Another good quarter Sales segments Upsides of NOK 1.2 million in Consumer Amounts in NOK 1.000' 18 000 Health sales of M-Gard® related to COVID- 16 000 Consumer Health 19 Adjuvant 14 000 Woulgan Final sales of Woulgan® in the third quarter Animal Health 12 000 as stock is
Slide 16: BetaGlucans Performance
BetaGlucans Performance Positive EBITDA for third straight quarter BetaGlucans Q3 YTD Amounts in NOK 1.000' 16 000 (Amounts in NOK 1.000) 2020 2019 2020 2019 Sales revenues 11 205 10 490 37 950 25 288 Gross profit 6 647 4 140 21 348 11 607 Sales Operating expenses -4 119 -6 651 -10 575 -18 311 11 00
Slide 17: ArcticZymes Technologies: Sales, Gross profit & EBITDA
ArcticZymes Technologies Lower COVID-19 upsides in Q3 Sales, Gross profit & EBITDA 50 000 Amounts in NOK 1.000' 40 000 Sales within high margin Sales segments secures solid gross Gross profit 30 000 EBITDA profit margin of 85% Enzymes segment is key 20 000 contributor EBITDA of 10.1 MNOK for Q3 10 0
Slide 18: Cash Flow
Cash Flow Positive cash flow development continues into Q3 Cash position Amounts in NOK 1.000' 80 000 25 000 70 000 20 000 60 000 15 000 50 000 Changes in Cash 10 000 Net Cash 40 000 69 660 5 000 56 158 30 000 - 35 667 20 000 31 300 28 190 22 056 -5 000 10 000 21 369 0 -10 000 Q1 2019 Q2 2019 Q3 201
Slide 19: Outlook
Chapter 5 Outlook
Slide 20: Outlook
Outlook Driving Strategic Profitability & Growth Strong Growth Inherent growth in all areas of the business Quarterly Fluctuations Natural part of B2B sales and should be expected Profitability Expect to deliver number 1 goal in achieving profitability during 2020 20
Slide 21: Thank you!
Thank you! arcticzymes.com